ECURE previously announced that the first patient dosed with ECUR-506 for OTC deficiency achieved a complete clinical ...

Clinical research organisation (CRO) Icon has begun the integration of Medidata Clinical Data Studio into its clinical ...

IGC Pharma has added HHS in Canada as a new clinical site for its Phase II CALMA trial of IGC-AD1 to treat agitation in ...

Onctura has dosed the first subject in the Phase II OCULE-01 trial of oral roginolisib in individuals with metastatic uveal ...

The US is set to withdraw from the WHO following Trump's disagreements regarding the agency's handling of the Covid-19 ...

Biotech and biopharma companies have battled with a drought of private investment in recent years but could now face government funding cuts.

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

Of the 103 patients who completed the Phase III trial, more than half saw remission from a drug-induced condition.

NACE has collaborated with 17 Australian general practices and allergy clinics to launch the ARISE trial for young people with hay fever.

Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing Alzheimer's symptoms by 50%.

Results from the trial showed that patients started with an average HbA1c level of 8.1% and dropped to 7.2%. Credit: Shutterstock / Rost9. Individuals with type 1 diabetes (T1D) have demonstrated ...

Immunovant will use results from its Phase III myasthenia gravis study to support pipeline candidate IMVT-1402 over the trial ...